SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow
Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

 

 

Press Release dated July 29, 2010

Contact:		Trinity Biotech plc		Lytham Partners LLC
		Kevin Tansley		Joe Diaz, Joe Dorame & Robert Blum
		(353)-1-2769800		602-889-9700
		E-mail: kevin.tansley@trinitybiotech.com

Trinity Biotech Announces Quarter 2 Financial Results
$47.4m profit on coagulation divestiture
EPS for the quarter increases to 15.5 cent

DUBLIN, Ireland (July 29, 2010).... Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2010.

Quarter 2 Results

Total revenues for the quarter were $22.6m which compares to $32.3m in quarter 2, 2009, a decrease of 30%. This decrease is principally due to the divestiture of the coagulation product line which was effective from 30 April 2010.

Point-of-care revenues for the quarter decreased by 32.1% when compared to quarter 2, 2009. This was due to particularly high sales in quarter 2, 2009 and the continued impact of the company’s decision to restrict shipments to a major HIV customer due to credit related issues. Compared to quarter 1, 2010 point of care revenues were down 8% which represents a normal level of fluctuation and were in line with our expectations for the quarter.

Continuing clinical laboratory (i.e. excluding coagulation) revenues were $14.2m which represents a decrease of 5.9% when compared to $15.1m in quarter 2, 2009. However, if the impact of no longer selling fully direct in UK, France and Germany and the impact of foreign exchange are excluded, there would have been organic growth of approximately 2% for the quarter. Compared to quarter 1, 2010 continuing clinical laboratory sales have increased by 6.8%.

Lower coagulation revenues reflect the divestiture of this product line at the end of the first month of the quarter — 30 April 2010.

Revenues for quarter 2 by key product area were as follows:

		2009				2010				Increase/				2010
		Quarter 2				Quarter 2				Decrease				Quarter 1
		US$’000				US$’000				%				US$’000
Point-of-Care			5,908				4,011				-32.1	%			4,362
Continuing Clinical Laboratory			15,062				14,178				-5.9	%			13,274
Continuing operations*			20,970				18,189				-13.3	%			17,636
Coagulation			11,332				4,437				-60.8	%			11,377
Total			32,302				22,626				-30.0	%			29,013

Gross profit for the quarter amounted to $11.2m representing a gross margin of approximately 49.3%. This represents an increase of 3.7% over the same period in 2009. The improvement in gross margin is largely attributable to the divestiture of coagulation, which traditionally had been our lowest gross margin product line. Excluding instrument service costs for the quarter, the gross margin would be 52.1%.

Research and Development expenses for the quarter amounted to $1.2m, which represents a decrease of 32.7% compared to quarter 2, 2009. Similarly SG&A expenses have fallen by 24.9% from $9.0m in quarter 2 of 2009 to $6.8m in the current quarter. In both cases the principal driver for the reduction has been the transfer of R&D, sales and administrative personnel to Stago as part of the coagulation divestiture.

Net financial income for the quarter was $152,000 which compares to an expense of $348,000 in quarter 2, 2009. This improvement is attributable to the increase in cash balances to $50m and the elimination of bank debt during the quarter.

Operating profit decreased from $3.8m in quarter 2, 2009 to $3.5m in the current quarter due to the coagulation divestiture. However, the operating margin for the quarter has increased to 15.5% which represents a significant improvement compared to 11.9% in quarter 2, 2009.

During the quarter the company recognised a profit on the sale of its coagulation product line of $47.4m. This reflects the sales proceeds of $90m less the carrying value of the assets divested and associated costs. This is partly offset by a once-off charge of $0.3m in relation to the restructuring of the company’s HIV manufacturing activities, which will result in improved profitability from early 2011 onwards.

Excluding non-recurring items, profit after tax increased from $3m in quarter 2, 2009 to $3.3m, an increase of 8.7%. Similarly, EPS for the quarter increased from 14.4 cent per share to 15.5 cent per share, an increase of 7.6%.

The tax charge for the quarter was $40,000 which includes a tax credit of $354,000 relating to the coagulation divestiture and a tax charge of $394,000 relating to ongoing activities. The latter represents an effective tax rate of 10.8%.

The following table excludes the impact of the non-recurring items:

		2009				2010
		Quarter 2				Quarter 2				Increase
		US$’000				US$’000				%
Profit before tax			3,493				3,661				4.8	%
Income Tax expense			488				394
Profit after tax			3,005				3,267				8.7	%
Basic EPS — US cents			14.4				15.5				7.6	%
Diluted EPS — US cents			14.4				15.1				4.9	%

From a cash perspective the Company generated $5.9m of cash from operations which is an increase of almost 40% compared with the same period in 2009. In quarter 2, 2010 the company generated free cash flows of $4.4m, compared to $2.2m for the corresponding quarter in 2009.

Coagulation Divestiture

During the quarter the company completed the divesture of its coagulation product line to Stago. At the time of divestiture, coagulation represented approximately 40% of the company’s revenues. The principal impacts of this divestiture have been as follows:

•

The recognition of a profit on the sale of $47.4m.

•

The receipt of cash (net of expenses) to date of $66.5m. The company will receive a further $22.5m in deferred consideration over the next 2 years. This has allowed the company to eliminate all bank debt and increase cash reserves to $50m.

•

A significant reduction in the company’s cost base following the transfer of 320 employees to Stago.

•

A reduction in property, plant and equipment of $6.8m and goodwill and intangible assets of $12.2m.

•

A reduction in working capital of $23.5m.

Notwithstanding the above, the company’s on-going earnings are expected to be 100-110% of pre-divestiture levels.

Comments

Commenting on the results, Kevin Tansley, Chief Financial Officer, said “ This was a very significant quarter for the company. We divested our coagulation product line for a profit of over $47m. This enabled us to fully eliminate our bank debt and build up significant cash reserves. We also posted EPS before non-recurring items of 15.5 cent in the quarter which represents an increase of 7% over quarter 2 last year. With cash from operations of $5.9m and free cash flows of $4.4m the company is now generating significant cash. With the improved profitability and strong cash flows the company is performing very strongly”.

Ronan O’Caoimh, CEO of Trinity Biotech, stated, “The results this quarter show that we are continuing to succeed in our stated goal of EPS growth. We have shown that without coagulation we have been able to continue our growth in profitability and I can confirm our expectation that earnings will be 100-110% of pre-divestiture levels. We have no debt, cash of $3.43 per share, with cash per share increasing at over 5 cents per month.

Our new diabetes A1c instrument will launch before year end. We have aggressively implemented our new point-of-care strategy and have created a large R&D team in San Diego and expanded our Irish R&D team. They are working on 9 new point-of-care products with the first launches expected in approximately 18 months.”

Forward-looking statements in this release are made pursuant to the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company’s website: www.trinitybiotech.com.

Trinity Biotech plc
Consolidated Income Statements

		Three Months				Three Months				Six Months				Six Months
		Ended				Ended				Ended				Ended
		June 30,				June 30,				June 30,				June 30,
(US$000’s except share data)		2010				2009				2010				2009
		(unaudited)				(unaudited)				(unaudited)				(unaudited)
Revenues			22,626				32,302				51,639				63,408
Cost of sales (excluding service costs)			(10,849	)			(16,306	)			(25,283	)			(31,729	)
Gross profit (excluding service costs)			11,777				15,996				26,356				31,679
Gross profit % (excluding service costs)			52.1	%			49.5	%			51.0	%			50.0	%
Cost of sales — instrument servicing costs			(620	)			(1,256	)			(1,670	)			(2,626	)
Gross profit (including service costs)			11,157				14,740				24,686				29,053
Gross profit % (including service costs)			49.3	%			45.6	%			47.8	%			45.8	%
Other operating income			527				68				583				272
Research & development expenses			(1,198	)			(1,781	)			(2,992	)			(3,557	)
Selling, general and administrative expenses			(6,766	)			(9,011	)			(14,705	)			(18,612	)
Indirect share based payments			(211	)			(175	)			(387	)			(273	)
Operating profit			3,509				3,841				7,185				6,883
Non-recurring items			47,061				—				47,061				—
Financial income			268				3				278				4
Financial expenses			(116	)			(351	)			(357	)			(640	)
Net financing income/(expense)			152				(348	)			(79	)			(636	)
Profit before tax			50,722				3,493				54,167				6,247
Income tax expense on operating activities			(394	)			(488	)			(682	)			(738	)
Income tax credit on non-recurring items			354				—				354				—
Profit for the period			50,682				3,005				53,839				5,509
Profit for the period (excluding non-recurring items)			3,267				3,005				6,424				5,509
Earnings per ADR (US cents)			240.1				14.4				255.2				26.4
Earnings per ADR (US cents) — excluding non-recurring items			15.5				14.4				30.4				26.4
Diluted earnings per ADR (US cents)			235.0				14.4				251.2				26.4
Diluted earnings per ADR (US cents) — excluding non-recurring items			15.1				14.4				30.0				26.4
Weighted average no. of ADRs used in computing basic earnings per ADR			21,109,023				20,856,868				21,098,574				20,855,638

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Balance Sheets

		June 30,				March 31,				December 31,
		2010				2010				2009
		US$ ’000				US$ ’000				US$ ’000
		(unaudited)				(unaudited)				(audited)
ASSETS
Non-current assets
Property, plant and equipment			5,339				12,131				12,174
Goodwill and intangible assets			35,127				46,247				44,822
Deferred tax assets			4,073				5,627				5,801
Other assets			11,762				1,330				1,212
Total non-current assets			56,301				65,335				64,009
Current assets
Inventories			18,064				40,033				39,198
Trade and other receivables			28,592				20,415				22,931
Income tax receivable			257				260				229
Cash and cash equivalents			50,042				6,222				6,078
Total current assets			96,955				66,930				68,436
TOTAL ASSETS			153,256				132,265				132,445
EQUITY AND LIABILITIES
Equity attributable to the equity holders of the parent
Share capital			1,083				1,080				1,080
Share premium			160,817				160,739				160,683
Accumulated deficit			(32,811	)			(83,717	)			(87,070	)
Translation reserve			(544	)			(385	)			206
Other reserves			4,144				4,241				4,445
Total equity			132,689				81,958				79,344
Current liabilities
Interest-bearing loans and borrowings			246				13,429				12,625
Income tax payable			148				207				24
Trade and other payables			12,241				11,732				12,844
Derivative Financial Instruments			406				279				58
Provisions			50				50				50
Total current liabilities			13,091				25,697				25,601
Non-current liabilities
Interest-bearing loans and borrowings			294				16,409				19,231
Other payables			607				38				59
Deferred tax liabilities			6,575				8,163				8,210
Total non-current liabilities			7,476				24,610				27,500
TOTAL LIABILITIES			20,567				50,307				53,101
TOTAL EQUITY AND LIABILITIES			153,256				132,265				132,445

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Statement of Cash Flows

		Three Months				Three Months				Six Months				Six Months
		Ended				Ended				Ended				Ended
		June 30,				June 30,				June 30,				June 30,
		2010				2009				2010				2009
(US$000’s)		(unaudited)				(unaudited)				(unaudited)				(unaudited)
Cash and cash equivalents at beginning of period			6,222				2,589				6,078				5,184
Operating cash flows before changes in working capital			4,415				4,928				9,326				9,009
Changes in Working Capital			1,468				(707	)			1,689				(2,476	)
Cash generated from operations			5,883				4,221				11,015				6,533
Net Interest and Income taxes paid			(352	)			(133	)			(577	)			(393	)
Capital Expenditure (net)			(1,111	)			(1,886	)			(3,435	)			(4,387	)
Repayment of bank debt			(27,117	)			—				(29,556	)			(2,146	)
Proceeds from sale of Coagulation Product Line			66,517				—				66,517				—
Cash and cash equivalents at end of period			50,042				4,791				50,042				4,791

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company’s accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 29, 2010